Clinical trials
Participation clinical trials
Below are recruiting participation clinical trials, each written for real people, not researchers. We’re tracking 2,211 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07378644RecruitingPhase 2/Phase 3
Testing SKY-0515 for Huntington's disease
This trial tests a new drug called SKY-0515 in people with Huntington's disease. The goal is to see if it can safely improve symptoms or slow the disease down.
Buenos Aires, Buenos AiresAges 25 years+ - NCT06848088Enrolling by invitationPhase 2
Long-term health study for melanoma participants
This study checks on the long-term health of adults with melanoma who took part in a previous treatment study. It aims to see how participants are doing over time after receiving the new therapy.
Los Angeles, CaliforniaAges 18 years+ - NCT07555483RecruitingPhase 3
Weekly injection vs IV infusion for alpha-1 antitrypsin deficiency
This trial tests whether a new weekly injection form of alpha-1 antitrypsin replacement therapy (a protein your body lacks) works as well as the standard IV infusion you may currently receive. The goal is to offer a more convenient treatment option for people with alpha-1 antitrypsin deficiency (a genetic lung condition).
Birmingham, AlabamaAges 18–80 - NCT06044337Enrolling by invitationPhase 3
Long-term safety study of litifilimab for skin lupus
This study is a long-term follow-up for people who already completed a 52-week study of the study drug litifilimab for active skin lupus. It will check the safety of continued treatment and see if it keeps helping symptoms.
Birmingham, AlabamaAges 18 years+ - NCT07218380RecruitingPhase 3
Study of Vepugratinib for advanced bladder or urinary tract cancer
This trial tests an experimental drug called Vepugratinib for people with advanced urinary tract cancer that has a specific change in the FGFR3 gene. It may be an option if you haven't had other treatments for advanced cancer and are looking for a new approach.
Huntsville, AlabamaAges 18 years+ - NCT05755386RecruitingPhase 3
Iptacopan for idiopathic IC-MPGN with heavy protein in urine
This trial tests iptacopan (an add-on medicine) in people with idiopathic immune-complex membranoproliferative glomerulonephritis (IC-MPGN), a kidney disease causing significant protein loss in urine. It aims to improve kidney outcomes and safety when added to standard treatments.
Los Angeles, CaliforniaAges 12–60 - NCT07095686Enrolling by invitationPhase 1/Phase 2
Personalized treatment for CHCHD10 ALS
This trial tests a personalized medicine approach for people with a specific genetic form of ALS caused by changes in the CHCHD10 gene. A custom-designed antisense oligonucleotide (a type of genetic therapy) is used to target the underlying cause of the disease.
New York, New YorkAges 18 years+ - NCT06106945RecruitingPhase 1/Phase 2
AZD0305 alone or with other drugs for multiple myeloma
This trial tests a new drug called AZD0305, either by itself or combined with other cancer drugs, for people with multiple myeloma. It aims to see if the treatment is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT06859099Enrolling by invitationPhase 3
Long-term safety study of Riliprubart for CIDP
This study checks the long-term safety and how well riliprubart works for people with chronic inflammatory demyelinating polyneuropathy (CIDP). It is for those who have already taken riliprubart in a previous study.
Homewood, AlabamaAges 18 years+ - NCT06712654RecruitingPhase 2
Testing AP306 for high phosphate in dialysis patients
This trial tests a new medication called AP306 for people on hemodialysis who have high blood phosphate. It aims to see if the drug is safe, tolerable, and helps lower phosphate levels.
Huntsville, AlabamaAges 18 years+ - NCT07160179RecruitingPhase 1/Phase 2
Study of an eye injection for geographic atrophy
This study tests a new medicine (ABBV-6628) given as an injection into the eye to see how well it works and how it moves through the body for people with geographic atrophy (an advanced form of dry age-related macular degeneration). It may help slow vision loss from this condition.
Carmel, IndianaAges 50 years+ - NCT07065240RecruitingPhase 2
Study of SPT-300 for major depression with or without anxiety
This trial tests an experimental oral medication, SPT-300, for people with major depressive disorder, even if they also have mild anxiety. The goal is to see if it helps improve mood safely.
Chino, CaliforniaAges 18–65 - NCT07457567Recruiting
Social brain study in healthy adults
This study looks at how the brain works when we interact with others. It uses brain imaging to understand the 'social brain' in healthy adults.
New Haven, ConnecticutAges 18 years+ - NCT07525544RecruitingPhase 1
Safety Study of VH4770359 in Healthy Adults
This is an early-stage safety study testing a new investigational drug (VH4770359) in healthy volunteers. Researchers want to understand how the body processes the drug and ensure it is safe and well-tolerated.
Baltimore, MarylandAges 18–55 - NCT04974138RecruitingPhase 4
Preventing first stroke in people with high-risk blood pressure
This trial tests whether a study medicine regimen can help prevent a first stroke in people with hard-to-control “high homocysteine” risk factors linked to a specific gene type. You may qualify if you have certain blood pressure levels, a specific MTHFR gene result, and related blood test findings.
Bengbu, AnhuiAges 45–74 - NCT04974151RecruitingPhase 4
Prevention trial for stroke risk in people with high blood pressure
This trial tests an approach to prevent first-time stroke and heart problems in people with high blood pressure who also have a specific genetic test result (MTHFR 677 TT). It may help by lowering risk before a first stroke happens.
Bengbu, AnhuiAges 45–74 - NCT04993690RecruitingPhase 1
Oral LP-168 for relapsed or hard-to-treat B-cell lymphoma
This Phase 1 study tests whether an oral medicine called LP-168 can be given safely and possibly work against lymphoma that has come back or is not responding to standard treatment. It’s mainly looking for safety, but your results could help determine whether the drug should be studied further.
Beijing, Beijing MunicipalityAges 18–80 - NCT04998396RecruitingPhase 1/Phase 2
Gene therapy trial for Canavan disease in young children
This Phase 1/2 trial tests an AAV9 gene therapy to treat Canavan disease. It aims to improve disease-related findings in children whose genetic test confirms ASPA gene changes.
Oakland, CaliforniaAges Up to 2.5 years - NCT05005403RecruitingPhase 1
Testing azirkitug for lung, head/neck, and other solid cancers
This Phase 1 study tests how a new medicine (azirkitug) behaves in the body and how safe it is, given by IV infusion alone or with other cancer drugs. It may help people with several advanced solid tumor cancers, especially after standard treatments have stopped working.
Duarte, CaliforniaAges 18 years+ - NCT05022940Recruiting
Track recovery and participation after adult brain injury rehab
This study follows adults with traumatic brain injury (TBI) during and after rehabilitation, to better understand how recovery and daily participation change over time. It may help improve rehab programs for people like you in the future.
Montreal, QuebecAges 17 years+ - NCT05030597Recruiting
PET scans targeting FAP for oral cancer and recurrence
This trial uses a special PET scan that targets a substance called FAP to better find oral squamous cell cancer and check for recurrence. It may help doctors see where cancer activity is and guide treatment planning, especially around surgery and (for some people) neoadjuvant therapy before surgery.
Wuhan, HubeiAges 18–70 - NCT05076175RecruitingPhase 2/Phase 3
Oral ozanimod for children with moderate to severe ulcerative colitis
This trial tests whether an oral medicine called ozanimod can improve ulcerative colitis (UC) in children whose disease is moderate to severe. It’s meant for kids who didn’t fully respond—or couldn’t tolerate—standard UC treatments.
Phoenix, ArizonaAges 2–17 - NCT05090891RecruitingPhase 2
Study medicine INCB000928 for fibrodysplasia ossificans progressiva
This Phase 2 study tests whether INCB000928 can safely help people with fibrodysplasia ossificans progressiva (FOP). It mainly looks at whether the treatment is effective and well-tolerated, and it involves scheduled whole-body scans using low-dose X-rays.
Rochester, MinnesotaAges 2–99 - NCT05090943Recruiting
Adult tic disorder registry for patients in France
This study is a registry, meaning it collects information about adults with tic disorders over time. It may help researchers better understand tic disorders and improve future care.
Clermont-FerrandAges 18 years+
Hear when a new Participation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for participation?
- Yes. Clin2 currently lists 2,211 recruiting participation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a participation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a participation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.